Literature DB >> 18823815

Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay.

P A C Maple1, P Rathod, E Smit, J Gray, D Brown, E H Boxall.   

Abstract

BACKGROUND: Determination of Varicella Zoster virus (VZV) immune status in pregnant women without history of chickenpox is important in identifying those who genuinely need VZV immune globulin prophylaxis following significant exposure to chickenpox or shingles. Immune status testing requires highly sensitive and specific immunoassays for timely and accurate results.
OBJECTIVES: To compare the performance of DiaSorin LIAISON and Biomerieux VIDAS VZV-IgG assays with reference to a VZV-IgG time-resolved fluorescence immunoassay (TRFIA). STUDY
DESIGN: A panel of sera collected from 65 pregnant contacts of VZV and 62 individuals tested for VZV immunity was tested in all three assays. Dose-response curves were generated using International Standards W1044 and 90/690.
RESULTS: Sensitivity and specificity of VIDAS compared to VZV-TRFIA was 54.5% and 97.9% respectively and for LIAISON compared to VZV-TRFIA was 67% and 100% respectively. Both assays correlated well with TRFIA with R2 correlation coefficients of 0.79 and 0.76 respectively. Dose-response curves showed both Standards behaved in a similar manner in each assay. For VIDAS, the test cut-off value of 0.9 correlated with 275-280mIU/ml and for LIAISON a cut-off value of 150mIU/ml correlated with 208-219mIU/ml.
CONCLUSIONS: By dose-response data and in comparison with TRFIA, LIAISON is more sensitive and specific than VIDAS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18823815     DOI: 10.1016/j.jcv.2008.08.012

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

Review 1.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

2.  Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers.

Authors:  S L R McDonald; P A C Maple; N Andrews; K E Brown; K L Ayres; F T Scott; M Al Bassam; A A Gershon; S P Steinberg; J Breuer
Journal:  J Virol Methods       Date:  2010-12-28       Impact factor: 2.014

3.  Follow-up of pregnant women exposed to chicken pox: an audit of relationship between level of antibody and development of chicken pox.

Authors:  E H Boxall; P A C Maple; P Rathod; E Smit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-01       Impact factor: 5.103

4.  Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.

Authors:  Catia T Perciani; Manmeet Sekhon; Sabrina Hundal; Bashir Farah; Mario A Ostrowski; A Omu Anzala; Lyle R McKinnon; Walter Jaoko; Kelly S MacDonald
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

5.  Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation.

Authors:  Marcia M L Kho; Willem Weimar; S Reshwan K Malahe; Joke M Zuijderwijk; Ronella de Kuiper; Marieken J Boer-Verschragen; Annemiek A van der Eijk; Dennis A Hesselink; Marlies E J Reinders; Nicole M van Besouw
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

6.  A Simple-to-Perform ifn-γ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Mathilde Boccard; Anne Conrad; William Mouton; Florent Valour; Chantal Roure-Sobas; Emilie Frobert; Barbara Rohmer; Vincent Alcazer; Hélène Labussière-Wallet; Hervé Ghesquières; Fabienne Venet; Karen Brengel-Pesce; Sophie Trouillet-Assant; Florence Ader
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

7.  Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy.

Authors:  S Kumakura; H Shibata; K Onoda; N Nishimura; C Matsuda; M Hirose
Journal:  Epidemiol Infect       Date:  2013-04-11       Impact factor: 2.451

8.  Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.

Authors:  Ali Manouchehrinia; Radu Tanasescu; Huner Kareem; Oltita P Jerca; Fouzia Jabeen; Rachelle Shafei; Judith Breuer; Keith Neal; William Irving; Cris S Constantinescu
Journal:  J Neurovirol       Date:  2017-09-11       Impact factor: 2.643

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.